Factor V leiden and the risk of proximal venous thrombosis after total hip arthroplasty

Journal of Arthroplasty

Volumn 13, Issue 2, 1998, Pages 207-210

  Woolson, Steven T ^a,b   Zehnder, James L ^a   Maloney, William J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Complications; Deep vein thrombosis; Hip arthroplasty; Thrombosis risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5; WARFARIN;

ARTICLE; DEEP VEIN THROMBOSIS; FIBRINOLYTIC THERAPY; GENOTYPE; HUMAN; LEG COMPRESSION; MAJOR CLINICAL STUDY; POSTOPERATIVE THROMBOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; TOTAL HIP PROSTHESIS; TREATMENT PLANNING;

EID: 0031931131     PISSN: 08835403     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0883-5403(98)90101-2     Document Type: Article

References (15)

1. Clagett GP, Anderson FA, Heit J et al: Prevention of venous thromboembolism (Fourth ACCP Consensus Conference on Antithrombotic Therapy). Chest 108: 312S, 1995
2. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517, 1994
3. Bertina RM, Koeleman BP, Koster T et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994
4. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP: Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 74:449, 1995
5. Woolson ST, McCrory BA, Walter JF et al: B-mode ultrasound scanning in the detection of proximal venous thrombosis after total hip replacement. J Bone Joint Surg 72A:983, 1990
6. Bauer KA: Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 74:94, 1995
7. Heeb MJ, Kojima Y, Greengard JS, Griffin JH: Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 85:3405, 1995
8. Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269:31869, 1994
9. Kalafatis M, Bertina RM, Rand MD, Mann KG: Characterization of the molecular defect in factor VR506Q. J Biol Chem 270:4053, 1995
10. Dahlback B: Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis: functional tests and DNA-based assays, pros and cons. Thromb Haemost 73:739, 1995
11. de Ronde H, Bertina RM: Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72:880, 1994
12. Voelkerding KV, Wu L, Williams EC et al: Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C and establishment of cell line controls. Am J Clin Pathol 106:100, 1996
13. Zehnder JL, Benson RC: Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol 106:107, 1996
14. Crowther MA, Hayward CPM, Hamid C et al: Activated protein C resistance is not associated with postoperative deep vein thrombosis in patients undergoing hip or knee surgery. Blood 86:616a, 1995
15. Woolson S: Intermittent pneumatic compression to prevent proximal deep venous thrombosis during and after total hip replacement. J Bone Joint Surg 73A:983, 1996